RxDoctor Payments Data

Suntharo Ly, MD

Interventional Cardiology · Chandler, AZNPI 1134208168

Payments from drug & device makers

$16,382in general payments, 2019–2025

Across 374 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Novartis$767
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$734
  • Heartflow, Inc.$717
  • Johnson & Johnson$577
  • Abbott$527
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$8,05349%
  • Food & beverage$8,04149%
  • Education$2882%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,382 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$748,556
Medicare patients
1,347
Services billed
6,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$420,059
XareltoRivaroxaban181$226,230
EntrestoSacubitril/Valsartan73$95,069
BrilintaTicagrelor69$57,913
FarxigaDapagliflozin Propanediol11$15,260
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,639
Ranolazine ErRanolazine39$5,459
Flecainide Acetate89$4,842
Atorvastatin Calcium519$4,077
SotalolSotalol Hcl184$4,043
Metoprolol Succinate297$3,680
Sotalol AfSotalol Hcl101$3,625
Isosorbide Mononitrate ErIsosorbide Mononitrate224$3,347
ClopidogrelClopidogrel Bisulfate224$3,038
Losartan Potassium267$2,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$420,059306 claims
Johnson & JohnsonXarelto$577$226,230181 claims
NovartisEntresto$767$95,06973 claims
AstraZenecaBrilinta, Farxiga$477$73,17380 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →